|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang J, Cogdell D, Yang D, Hu L, Li H,
Zheng H, Du X, Pang Y, Trent J, Chen K and Zhang W: Deletion of the
WWOX gene and frequent loss of its protein expression in human
osteosarcoma. Cancer Lett. 291:31–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sparks AB, Peterson SN, Bell C, Loftus BJ,
Hocking L, Cahill DP, Frassica FJ, Streeten EA, Levine MA, Fraser
CM, et al: Mutation screening of the TNFRSF11A gene encoding
receptor activator of NF kappa B (RANK) in familial and sporadic
Paget's disease of bone and osteosarcoma. Calcif Tissue Int.
68:151–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sadikovic B, Yoshimoto M, Chilton-MacNeill
S, Thorner P, Squire JA and Zielenska M: Identification of
interactive networks of gene expression associated with
osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol
Genet. 18:1962–1975. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ueda K, Cardarelli C, Gottesman MM and
Pastan I: Expression of a full-length cDNA for the human ‘MDR1’
gene confers resistance to colchicine, doxorubicin, and
vinblastine. Proc Natl Acad Sci USA. 84:3004–3008. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jia M, Hu J, Li W, Su P, Zhang H, Zhang X
and Zhou G: Trps1 is associated with the multidrug resistance of
osteosarcoma by regulating MDR1 gene expression. FEBS Lett.
588:801–810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu YS, Xin J, Hu Y, Zhang L and Wang J:
Analyzing the genes related to Alzheimer's disease via a network
and pathway-based approach. Alzheimers Res Ther. 9:292017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cowley MJ, Pinese M, Kassahn KS, Waddell
N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S and Wu J: PINA
v2.0: Mining interactome modules. Nucleic Acids Res. 40:(Database
Issue). D862–D865. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Menche J, Sharma A, Kitsak M, Ghiassian
SD, Vidal M, Loscalzo J and Barabási AL: Disease networks.
Uncovering disease-disease relationships through the incomplete
interactome. Science. 347:12576012015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia P, Zheng S, Long J, Zheng W and Zhao
Z: dmGWAS: Dense module searching for genome-wide association
studies in protein-protein interaction networks. Bioinformatics.
27:95–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J, Duncan D, Shi Z and Zhang B:
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update 2013.
Nucleic Acids Res. 41:(Web Server Issue). W77–W83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, Bardes EE, Aronow BJ and Jegga AG:
ToppGene Suite for gene list enrichment analysis and candidate gene
prioritization. Nucleic Acids Res. 37:(Web Server Issue).
W305–W311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu Y, Pan Z, Hu Y, Zhang L and Wang J:
Network and pathway-based analyses of genes associated with
Parkinson's disease. Mol Neurobiol. 54:4452–4465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He X and Zhang J: Why do hubs tend to be
essential in protein networks? PLoS Genet. 2:e882006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeong H, Mason SP, Barabasi AL and Oltvai
ZN: Lethality and centrality in protein networks. Nature.
411:41–42. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu H, Kim PM, Sprecher E, Trifonov V and
Gerstein M: The importance of bottlenecks in protein networks:
Correlation with gene essentiality and expression dynamics. PLoS
Comput Biol. 3:e592007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wuchty S: Controllability in protein
interaction networks. Proc Natl Acad Sci USA. 111:7156–7160. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xing P, Liao Z, Ren Z, Zhao J, Song F,
Wang G, Chen K and Yang J: Roles of low-density lipoprotein
receptor-related protein 1 in tumors. Chin J Cancer. 35:62016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang J, Annala M, Ji P, Wang G, Zheng H,
Codgell D, Du X, Fang Z, Sun B, Nykter M, et al: Recurrent
LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell
motility in human osteosarcoma. J Hematol Oncol. 7:762014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shibayama T, Okamoto T, Nakashima Y, Kato
T, Sakurai T, Minamiguchi S, Kataoka TR, Shibuya S, Yoshizawa A,
Toguchida J and Haga H: Screening of BCOR-CCNB3 sarcoma using
immunohistochemistry for CCNB3: A clinicopathological report of
three pediatric cases. Pathol Int. 65:410–414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bousquet M, Noirot C, Accadbled F, de
Gauzy Sales J, Castex MP, Brousset P and Gomez-Brouchet A:
Whole-exome sequencing in osteosarcoma reveals important
heterogeneity of genetic alterations. Ann Oncol. 27:738–744. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saalfrank A, Janssen KP, Ravon M,
Flisikowski K, Eser S, Steiger K, Flisikowska T, Müller-Fliedner P,
Schulze É, Brönner C, et al: A porcine model of osteosarcoma.
Oncogenesis. 5:e2102016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yotov WV, Hamel H, Rivard GE, Champagne
MA, Russo PA, Leclerc JM, Bernstein ML and Levy E: Amplifications
of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes
Cancer. 26:62–69. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xi Y and Chen Y: PTEN plays dual roles as
a tumor suppressor in osteosarcoma cells. J Cell Biochem.
118:2684–2692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kersting C, Gebert C, Agelopoulos K,
Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M,
Gosheger G, Brandt B, et al: Epidermal growth factor receptor
expression in high-grade osteosarcomas is associated with a good
clinical outcome. Clin Cancer Res. 13:2998–3005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mantovani FB, Morrison JA and Mutsaers AJ:
Effects of epidermal growth factor receptor kinase inhibition on
radiation response in canine osteosarcoma cells. BMC Vet Res.
12:822016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deel MD, Li JJ, Crose LE and Linardic CM:
A review: Molecular aberrations within hippo signaling in bone and
soft-tissue sarcomas. Front Oncol. 5:1902015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH,
He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, et al: Pro-apoptotic and
pro-autophagic effects of the Aurora kinase A inhibitor alisertib
(MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the
activation of mitochondria-mediated pathway and inhibition of p38
MAPK/PI3K/Akt/mTOR signaling pathway. Drug Des Devel Ther.
9:1555–1584. 2015.PubMed/NCBI
|
|
30
|
Li G, Cai M, Fu D, Chen K, Sun M, Cai Z
and Cheng B: Heat shock protein 90B1 plays an oncogenic role and is
a target of microRNA-223 in human osteosarcoma. Cell Physiol
Biochem. 30:1481–1490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma J, Huang K, Ma Y, Zhou M and Fan S: The
TAZ-miR-224-SMAD4 axis promotes tumorigenesis in osteosarcoma. Cell
Death Dis. 8:e25392017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng ZJ, Wu N, Liu Y, Shu KJ, Zou X, Zhang
RX, Pi CJ, He BC, Ke ZY, Chen L, et al: Evodiamine inhibits the
proliferation of human osteosarcoma cells by blocking PI3K/Akt
signaling. Oncol Rep. 34:1388–1396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tingting R, Wei G, Changliang P, Xinchang
L and Yi Y: Arsenic trioxide inhibits osteosarcoma cell
invasiveness via MAPK signaling pathway. Cancer Biol Ther.
10:251–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cai Y, Cai T and Chen Y: Wnt pathway in
osteosarcoma, from oncogenic to therapeutic. J Cell Biochem.
115:625–631. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Du X, Yang J, Yang D, Tian W and Zhu Z:
The genetic basis for inactivation of Wnt pathway in human
osteosarcoma. BMC Cancer. 14:4502014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alkhalaf M and Jaffal S: Potent
antiproliferative effects of resveratrol on human osteosarcoma
SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53
cascade. Free Radic Biol Med. 41:318–325. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deng Z, Liu X, Jin J, Xu H, Gao Q, Wang Y
and Zhao J: Histone deacetylase inhibitor trichostatin a promotes
the apoptosis of osteosarcoma cells through p53 signaling pathway
activation. Int J Biol Sci. 12:1298–1308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun Y, Xia P, Zhang H, Liu B and Shi Y:
P53 is required for Doxorubicin-induced apoptosis via the TGF-beta
signaling pathway in osteosarcoma-derived cells. Am J Cancer Res.
6:114–125. 2015.PubMed/NCBI
|
|
39
|
Suzuki S and Kulkarni AB: Extracellular
heat shock protein HSP90beta secreted by MG63 osteosarcoma cells
inhibits activation of latent TGF-beta1. Biochem Biophys Res
Commun. 398:525–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Y, Zhao RH, Tseng KF, Li KP, Lu ZG,
Liu Y, Han K, Gan ZH, Lin SC, Hu HY and Min DL: Sirolimus induces
apoptosis and reverses multidrug resistance in human osteosarcoma
cells in vitro via increasing microRNA-34b expression. Acta
Pharmacol Sin. 37:519–529. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu D, An F, He X and Cao X: Curcumin
inhibits the proliferation and invasion of human osteosarcoma cell
line MG-63 by regulating miR-138. Int J Clin Exp Pathol.
8:14946–14952. 2015.PubMed/NCBI
|
|
42
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-126 inhibits proliferation, migration, invasion and EMT in
osteosarcoma by targeting ZEB1. J Cell Biochem. 118:3765–3774.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yun HM, Park KR, Quang TH, Oh H, Hong JT,
Kim YC and Kim EC: 4-parvifuran inhibits metastatic and invasive
actions through the JAK2/STAT3 pathway in osteosarcoma cells. Arch
Pharm Res. 40:601–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
